Known targets — ChEMBL curated mechanism
POLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PRIM1PRIM2RRM1RRM2RRM2B
The experimentally established mechanism targets of Gemcitabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 known ✓ | P09884 | 2/20 | 0.61 |
| ▸ | PDE3A | Q14432 | 3/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.60 |
| ▸ | MTOR | P42345 | 1/20 | 0.60 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.60 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.60 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.60 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.49 |
| ▸ | ALB | P02768 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.49 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.49 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.49 |
| ▸ | CDA | P32320 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gemcitabine SCHEMBL6369622 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL9143689 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL18389585 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL18768286 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL9140896 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL19235640 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL13262185 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL9140892 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL20827751 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL12737233 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11957682-B2 | Compounds and methods for regulating, limiting, or inhibiting AVIL expression | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2024-04-16 | — | — | US | claimed |
| CN-114746753-A | Correlating AKR1C3 enzyme expression level through prostaglandin content and screening administration application | 深圳艾欣达伟医药科技有限公司 | 2022-07-12 | — | — | CN | claimed |
| CN-114555614-A | Anti-cancer compounds as non-PGP substrates | 深圳艾欣达伟医药科技有限公司 | 2022-05-27 | — | — | CN | claimed |
| WO-2021110085-A1 | METHOD FOR ASSOCIATING WITH EXPRESSION LEVEL OF AKR1C3 ENZYME VIA CONTENT OF PROSTAGLANDIN, AND USE OF SCREENING FOR DRUG ADMINISTRATION | 深圳艾欣达伟医药科技有限公司 | 2021-06-10 | — | — | WO | claimed |
| CN-112904026-A | Correlating AKR1C3 enzyme expression level through prostaglandin content and screening administration application | 深圳艾欣达伟医药科技有限公司 | 2021-06-04 | — | — | CN | claimed |
| WO-2021083310-A1 | ANTI-CANCER COMPOUNDS ACTING AS NON-PGP SUBSTRATE | 深圳艾欣达伟医药科技有限公司 | 2021-05-06 | — | — | WO | claimed |
| CN-110267650-A | Cancer of pancreas treatment | 杏国新药股份有限公司 | 2019-09-20 | — | — | CN | claimed |
| US-8906879-B2 | Combination for the treatment of cancer | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2014-12-09 | — | — | US | claimed |
| US-20130261075-A1 | COMBINATION | NOVARTIS AG (CH) | 2013-10-03 | — | — | US | claimed |
| CN-102365024-A | Compounds, compositions and methods for preventing metastasis of cancer cells | AKEBIA THERAPEUTICS INC | 2012-02-29 | — | — | CN | claimed |
| CN-1833636-A | Application of biphenyl cyclooctadiene lignin in treatment of tumour medicine | HU XUN (CN) | 2006-09-20 | — | — | CN | claimed |
| CN-1762450-A | Application of magnolia vine fruit in preparation of anti-tumor medicine or multi-medicine tolerant reversal agent | HU XUN (CN) | 2006-04-26 | — | — | CN | claimed |
| CN-116549455-A | Application of PLK4 inhibitor Centrinone in preparation of medicine for treating echinococcosis | 中国药科大学 | 2023-08-08 | — | — | CN | disclosed |
| CN-113281397-B | Method for tracking lysosomal content in monosysins | 中国科学技术大学 | 2023-04-25 | — | — | CN | disclosed |
| CN-110382532-B | anti-G-CSF antibodies and uses thereof | ME医疗公司 | 2023-04-14 | — | — | CN | disclosed |
| CN-114746753-A | Correlating AKR1C3 enzyme expression level through prostaglandin content and screening administration application | 深圳艾欣达伟医药科技有限公司 | 2022-07-12 | — | — | CN | disclosed |
| WO-2003043632-A2 | USE OF BISINDOLMALEIMIDE AND GEMCITABINE FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2003-05-30 | — | — | WO | disclosed |
| WO-2003028696-A2 | COMPOSITIONS FOR DELIVERY OF DRUG COMBINATIONS | CELATOR TECHNOLOGIES INC. (CA) | 2003-04-10 | — | — | WO | disclosed |
| WO-2002102363-A1 | BIOLOGICAL RESPONSE MODIFIER COMPOSITION AND USES THEREOF | LORUS THERAPEUTICS INC. (CA) | 2002-12-27 | — | — | WO | disclosed |
| WO-2002038164-A1 | COMBINATION PREPARATION OF A BIOLOGICAL RESPONSE MODIFIER AND AN ANTICANCER AGENT AND USES THEREOF | LORUS THERAPEUTICS INC. (CA) | 2002-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11957682-B2 | Compounds and methods for regulating, limiting, or inhibiting AVIL expression | VCL, HDLBP, VHL | POLA1 4275/4885PDE3A 2423/4885PDE4D 2158/4885 |
| US-20130261075-A1 | COMBINATION | DPYD, DUT, PAICS | POLA1 810/4885PDE3A 1454/4885PDE4D 428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.